Curie.Bio
VC Fund
Curie.Bio is a founder-focused seed-stage venture capital firm.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Curie.Bio invests in
Stages Curie.Bio invests in
Countries Curie.Bio invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 9 (75%)
- Therapeutics 6 (50%)
- Health Care 5 (42%)
- Medical 2 (17%)
- Fitness 1 (8%)
Stage
- Seed 11 (92%)
- Series A 1 (8%)
Country
- United States 7 (58%)
- United Kingdom 2 (17%)
- Australia 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexis Borisy
Co-Founder & Chairman
|
Co-Founder & Chairman | Total investments: 14 | Find email | |
Zach Weinberg
Co-Founder and CEO
|
Co-Founder and CEO | Total investments: 77 | Find email | |
Ben Auspitz
Managing Partner, Breakout Fund
|
Managing Partner, Breakout Fund | Total investments: 11 | Find email | |
Christoph Lengauer
Co-Founder and CSO
|
Co-Founder and CSO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M / Series A / Mar 17, 2026 | ||
|
Stealth Mode Biotech
|
Drug Discovery | Seed / Dec 20, 2024 | |
| Alkira Bio utilizes its proprietary LASEREDD® technology platform to discover therapeutic antibodies that target complex membrane proteins previously considered inaccessible, thereby advancing drug discovery into new frontiers. | Seed / Jul 04, 2024 | ||
| Tesseract Medical Research is a biotechnology and medical sciences business focused on delivering nutrition to meet unmet needs. | $20M / Seed / Jun 11, 2024 | ||
| Developing antibody-based therapies for autoimmune diseases by targeting immune cell activation and checkpoints. | Seed / Feb 28, 2024 | ||
|
Osteologic Therapeutics
|
Biotechnology company harnessing the skeleton to create transformative biologic medicines. | Seed / Nov 22, 2023 | |
FunctionRx
|
FunctionRx is a biotechnology company developing therapies for neurodegeneration. | Seed / Nov 21, 2023 | |
| Pioneering olfactory loss therapies, focused on age-related olfactory loss (presbyosmia). | Seed / Jul 24, 2023 | ||
| Cell Control Bio is a biotechnology company that develops in vivo CAR-T therapies and cell engineering platforms. | Seed / Dec 24, 2022 | ||
| Decrypt Biomedicine develops small molecule drugs that hit cryptic binding sites on validated but difficult-to-drug protein targets. | Seed / Dec 01, 2022 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Curie.Bio invest in?
Curie.Bio invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Curie.Bio?
Public channels for Curie.Bio include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Curie.Bio?
The team at Curie.Bio includes Alexis Borisy (Co-Founder & Chairman), Zach Weinberg (Co-Founder and CEO) and Ben Auspitz (Managing Partner, Breakout Fund). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
